

Freeform Search

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Term:

L8 same 17

 Display: Documents in Display Format: Starting with Number

 Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Interrupt

Search History

 DATE: Wednesday, September 29, 2004 [Printable Copy](#) [Create Case](#)

 Set Name Query
 side by side

 Hit Count Set Name
 result set

DB=USPT; PLUR=YES; OP=ADJ

L11 US-5976567-A.did.

1 L11

L10 US-5976567-A.did.

1 L10

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

L9 L8 same 17

43 L9

L8 nucleic acid or plasmid or dna

252175 L8

L7 lipid particles with encapsulated

211 L7

L6 6287591

9 L6

L5 L4 and l2

1 L5

L4 cationic liposome

4098 L4

L3 L2 same l1

0 L3

L2 SALP

271 L2

L1 cationic lipid or cationic amphiphile

7823 L1

END OF SEARCH HISTORY

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L9: Entry 38 of 43

File: EPAB

Nov 19, 1998

PUB-NO: WO009851278A2

DOCUMENT-IDENTIFIER: WO 9851278 A2

TITLE: HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES

PUBN-DATE: November 19, 1998

INVENTOR-INFORMATION:

NAME

COUNTRY

SEMPLE, SEAN C

KLIMUK, SANDRA K

HARASYM, TROY

HOPE, MICHAEL J

ANSELL, STEVEN M

CULLIS, PIETER

SCHERRER, PETER

DEBEYER, DAN

INT-CL (IPC): A61 K 9/00

EUR-CL (EPC): A61K009/127

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Previous Doc](#) [Next Doc](#) [Go to Doc#](#)
End of Result Set

☐ [Generate Collection](#) [Print](#)

L9: Entry 43 of 43

File: DWPI

Aug 12, 1999

DERWENT-ACC-NO: 1999-508459

DERWENT-WEEK: 200272

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Systemic delivery of serum-stable nucleic acid-lipid particles for cancer therapy

Basic Abstract Text (1):

NOVELTY - A serum-stable nucleic acid fully encapsulated within a lipid particle is administered by injection at a site distal to a neoplasia being treated in a mammal.

[Previous Doc](#) [Next Doc](#) [Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L9: Entry 36 of 43

File: USPT

May 30, 1995

DOCUMENT-IDENTIFIER: US 5419914 A
TITLE: Phospholipid analogue vesicle

Brief Summary Text (11):

The invention comprises a lipid particle including a succinimidyl moiety, preferably in the form of a N-ethylsuccinimidylthiol (NEST) moiety, extending from the surface of the particle in the absence of an extending ligand conjugate. The succinimidyl moiety is attached to a phospholipid molecule to form a succinimidyl phospholipid analogue, preferably in the form of a NEST-lipid entity and most preferably in the form of a N-(N-ethylsuccinimidylthio)phosphatidylethanolamine (NESTPE) moiety, specifically N-(N-ethylsuccinimidylthio) distearoylphosphatidylethanolamine (NEST-DSPE). At least one such phospholipid analogue is included in the outer phospholipid layer of the lipid particle with the succinimidyl moiety extending therefrom, to form a phospholipid analogue particle, which is capable of permitting the encapsulated contents of the lipid particle (e.g., a liposome) to enter the cell cytoplasmically in the essential absence of lysosomal degradation. Active agents which may be encapsulated in the lipid particles of the invention, and delivered intact to the cytoplasm, include lysosomal sensitive therapeutics (such as cytosine arabinosine) proteins and peptides, nucleic acids, oligonucleotides, genes, plasmids and other lysosomal sensitive agents.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L9: Entry 33 of 43

File: USPT

Jul 11, 2000

DOCUMENT-IDENTIFIER: US 6086913 A

TITLE: Liposomal delivery of AAV vectors

CLAIMS:

6. The composition of claim 1, wherein the lipid formulation comprises lipids complexed with the vector by

- a) combining the vector with cationic lipids in a detergent solution to provide a coated vector-lipid complex;
- b) contacting noncationic lipids with the coated vector-lipid complex to provide a solution comprising detergent, a vector-lipid complex and noncationic lipids; and
- c) removing the detergent from the solution of step b to provide a solution of serum-stable plasmid-lipid particles, wherein the plasmid is encapsulated in a lipid bilayer and the particles are serum-stable and have a size from about 50-150 nm.

7. The composition of claim 1, wherein the lipid formulation comprises lipids complexed with the vector by

preparing a mixture comprising cationic lipids and noncationic lipids in an organic solvent;

contacting an aqueous solution of said vector with the mixture to provide a clear single phase and

removing the organic solvent to provide a suspension of plasmid-lipid particles, wherein the plasmid is encapsulated in a lipid bilayer, and the particles are stable in serum and have a size of about 50-150 nm.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)